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CIRCULATION IN FIRST TRIMESTER, 






Pregnant women with congenital heart disease (CHD) have an increased risk of 
abnormal uteroplacental flow, measured from the second trimester onwards, which 
is associated with pregnancy complications affecting the mother and the fetus. 
Maternal right ventricular (RV) dysfunction has been suggested as a predisposing 
factor for impaired uteroplacental flow in these women. The aim of this study was to 
investigate the association of first-trimester uteroplacental flow measurements with 
prepregnancy maternal cardiac function and pregnancy complications in women with 
CHD, with particular focus on the potential role of RV (dys)function.
Methods 
This study included 138 pregnant women with CHD from the prospective ZAHARAIII 
study (Zwangerschap bij Aangeboren HARtAfwijkingen; Pregnancy and CHD). 
Prepregnancy clinical and echocardiographic data were collected. Clinical evaluation, 
echocardiography (focused on RV function, as assessed by tricuspid annular plane 
systolic excursion (TAPSE)) and uterine artery (UtA) pulsatility index (PI) measurements 
were performed at 12, 20 and 32 weeks of gestation. Univariable and multivariable 
regression analyses were performed to assess the association between prepregnancy 
variables and UtA-PI during pregnancy. The association between UtA-PI at 12 weeks 
and cardiovascular, obstetric and neonatal complications was also assessed.
Results 
On multivariable regression analysis, prepregnancy TAPSE was associated negatively 
with UtA-PI at 12 weeks of gestation (β= −0.026; P=0.036). Women with lower 
prepregnancy TAPSE (≤ 20 mm vs > 20 mm) had higher UtA-PI at 12 weeks (1.5 ± 0.5 
vs 1.2 ± 0.6; P=0.047). Increased UtA-PI at 12 weeks was associated with obstetric 
complications (P=0.003), particularly hypertensive disorders (pregnancy-induced 
hypertension and pre-eclampsia, P=0.019 and P=0.026, respectively).
Conclusions
In women with CHD, RV dysfunction before pregnancy seems to impact placentation, 
resulting in increased resistance in UtA flow, which is detectable as early as in the 
first trimester. This, in turn, is associated with pregnancy complications. Early 
monitoring of uteroplacental flow might be of value in women with CHD with pre-
existing subclinical RV dysfunction to identify pregnancies that would benefit from 
close obstetric surveillance.




Pregnant women with congenital heart disease (CHD) have a higher rate of impaired 
uteroplacental circulation compared with that in healthy pregnant women.1 This, in 
turn, is associated with maternal and neonatal complications.2 It has been suggested 
that maternal cardiac function may negatively influence remodeling of the spiral 
arteries by trophoblastic invasion of the myometrial portion of these vessels under 
the placental bed.3–5 We have reported previously an association between maternal 
cardiac dysfunction (particularly right ventricular (RV) and valvular dysfunction), 
before and during pregnancy, and impaired uteroplacental circulation in a cohort 
of women with CHD1, and in those with a specific type of CHD, such as tetralogy of 
Fallot and repaired aortic coarctation.6,7 In the latter groups, RV-function parameters 
were associated with abnormal uteroplacental flow measured in the second and 
third trimesters of pregnancy. This was also found in women with repaired aortic 
coarctation, which is a left-sided heart disease. We hypothesized that possible 
mechanisms for the negative influence of RV dysfunction on placentation may be 
venous congestion or right-to-left ventricular interaction leading to reduced cardiac 
output, resulting in impaired placental perfusion.8–10 The relationship between 
heart function and pregnancy complications is supported by the fact that women 
who develop pregnancy-related hypertensive disease have an increased propensity 
for the development of cardiac complications later in life or for diagnosis with a 
subclinical heart defect.11–13 The aim of this study was to investigate prospectively, in 
women with CHD, the association of uterine artery (UtA) flow measured in the first 
trimester with prepregnancy maternal cardiac function and pregnancy complications, 
with particular focus on the potential role of RV (dys)function as a predisposing factor 
for impaired uteroplacental flow.
Methods
This was a subanalysis of women recruited to the ZAHARA III study (Zwangerschap 
bij Aangeboren HARtAfwijkingen; Pregnancy and CHD), a prospective multicenter 
observational cohort study, in which pregnant women with CHD who presented 
at one of the participating centers at < 20 weeks’ gestation, and were ≥ 18 years 
of age, were enrolled between October 2011 and December 2015. Women who 
were HIV positive were excluded. The main aim of the ZAHARA III study was to 
investigate the relationship between maternal CHD and spontaneous preterm birth. 
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This subanalysis of the dataset focused on the association between prepregnancy 
maternal cardiac function and first-trimester uterine Doppler measurements, before 
14 weeks’ gestation, in women enrolled in the ZAHARAIII study. The ZAHARAIII study 
observed pregnant women with CHD according to the protocol of the previously 
published ZAHARAII study, with observations extended to the first trimester.14 All 
centers received approval of their medical ethics committee and all patients provided 
informed written consent.
Prepregnancy characteristics and follow-up
The prepregnancy baseline characteristics of pregnant women, recorded at the 
first prenatal visit, included underlying heart disease, cardiovascular history, 
obstetric history, maternal age, prepregnancy cardiac status (including New York 
Heart Association (NYHA) functional class, disease complexity according to Warnes 
et al.15, modified World Health Organization (WHO) risk class for maternal risk of 
cardiovascular complications according to the European Society of Cardiology 
guidelines16, electrocardiogram (ECG), laboratory results and echocardiography 
recordings), medication use, smoking and drug and alcohol use. Evaluation of 
pregnancy was performed at 12, 20 and 32 weeks of gestation, with the main focus 
on 12 weeks, including clinical evaluation, standardized echocardiography, ECG, 
laboratory evaluation (including serum hemoglobin and N-terminal peptide of 
proB-type natriuretic peptide (NT-proBNP)) and obstetric ultrasound examination. 
During the obstetric ultrasound examination, uteroplacental perfusion was studied 
by Doppler flow measurements (pulsatility index (PI) of the UtAs and the presence 
of early diastolic notch at 20 weeks of gestation), according to the guidelines of the 
International Perinatal Doppler Society.17 UtA-PI was considered abnormal if the value 
exceeded the 95th percentile reference value according to gestational age in healthy 
pregnant women.18
All echocardiographic examinations at 12 weeks’ gestation were performed according 
to disease-specific protocols and evaluated offline by three echocardiography 
experts (Y.M.H., P.G.P., A.S.S.), each of whom reviewed a part of the echocardiograms. 
Consistency and accuracy of the echocardiography data were checked by A.S.S.. 
Assessment of systolic and diastolic ventricular function, chamber quantification and 
valvular function were performed according to current guidelines.19–21 In patients 
with a single ventricle and a systemic right ventricle, measurement of subpulmonary 
ventricular function and ejection fraction of the systemic ventricle by Simpson’s 
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biplane method of discs are not validated, so eyeballing of the systemic ventricle 
was performed instead.21,22 Systemic ventricular dysfunction was defined as left 
ventricular (LV) ejection fraction < 45% and subpulmonary ventricular dysfunction as 
tricuspid annular plane systolic excursion (TAPSE) < 17 mm. Due to young age and 
high prevalence of volume overload of the right ventricle in this study population, 
TAPSE > 20 mm was considered normal.
Cardiac, obstetric and neonatal outcomes
Cardiovascular, obstetric and neonatal complications were recorded during pregnancy 
and up to 6 months after delivery. Extensive definitions for these complications have 
been published previously.14 Primary cardiovascular complications were defined as: 
the need for an urgent invasive cardiovascular procedure; heart failure (according 
to the guidelines of the European Society of Cardiology23 and documented by the 
attending physician); new-onset or symptomatic tachy- or bradyarrhythmia requiring 
new or extended treatment; thromboembolic events; myocardial infarction; cardiac 
arrest; cardiac death; endocarditis; and aortic dissection. Adverse obstetric outcome 
included: assisted delivery (vacuum or forceps extraction); Cesarean section (planned 
or emergency); pregnancy-induced hypertension (PIH); pre-eclampsia (PIH combined 
with proteinuria); eclampsia (pre-eclampsia with grand mal seizures); gestational 
diabetes mellitus, HELLP syndrome; hyperemesis gravidarum; non-cardiac death; 
placental abruption; postpartum hemorrhage ( > 1000 mL); premature labor; 
and preterm prelabor rupture of membranes ( < 37 weeks’ gestation). Neonatal 
complications were defined as: intrauterine ( ≥ 20 weeks’ gestation) and neonatal 
or infant (≤ 1 year after birth) death; admission to the neonatal intensive care unit; 
intraventricular hemorrhage (grade III–IV); neonatal respiratory distress syndrome; 
preterm birth (spontaneous and iatrogenic at < 37 weeks’ gestation); presence of 
CHD in the fetus; small-for-gestational age (birth weight < 10th percentile); and low 
birth weight (< 2500 g).
Statistical methods
Continuous variables with normal distribution are presented as mean ± SD, non-
normally distributed data as median and interquartile range and dichotomous 
variables as n (%). Longitudinal comparison of continuous variables within groups at 
two timepoints was performed using the paired Student’s t-test. For categorical data, 
McNemar’s test for related samples was used. For the comparison of dichotomous 
variables, the χ2 test or Fisher’s exact test was used, as appropriate. Univariable 
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and multivariable linear regression analyses were used to assess the association 
of prepregnancy maternal characteristics and cardiac function parameters before 
pregnancy and at 12 weeks of gestation with UtA-PI (at 12 and 20 weeks). Logistic 
regression models were used to assess the associations between cardiac, obstetric 
and neonatal complications and UtA-PI. Models were tested for confounding variables 
when needed. Variables associated with the studied endpoints (P<0.10) or considered 
relevant (based on literature13; P > 0.10) were entered into the multivariable model. 
The final model was constructed using backwards elimination of the least significant 
variable until all remaining variables were significantly associated with the endpoint. 
Patients with a systemic right ventricle were excluded from analyses of RV function. 
Statistical analysis was performed using SPSS version 23.0 (IBM Corp., Armonk, NY, 
USA).
Results
In the ZAHARA III study, 204 pregnant women were included initially. Eleven women 
were excluded, because of miscarriage (n=6), absence of CHD (n=4) or withdrawal 
of informed consent (n=1). In the current analysis, only pregnant women with 
uteroplacental flow examination at ≤ 14 weeks’ gestation were included, resulting in a 
study population of 138 pregnant women (two with a twin pregnancy).
Prepregnancy baseline characteristics
The types of underlying congenital heart disease in the study population are presented 
in Table 1. Correction of a primary congenital cardiac lesion or an additional cardiac 
lesion had been performed in 70.3% of women. Open-heart surgery was performed 
for correction of 87.6% of these lesions. Among the women with a shunt lesion, 
65.8% were corrected. Uncorrected cyanotic diseases were not present in this study 
population. The prevalence of left- and right-sided lesions within this population 
was not significantly different (P=0.745).Table 2 shows the prepregnancy maternal 
characteristics. History of miscarriage was reported in 24.6% of women, none had 
a history of pre-eclampsia and 13.8% smoked prior to pregnancy. A prepregnancy 
echocardiographic examination was performed in 93% of women (0 – 10.6 years 
before pregnancy). Of these examinations, 65.2% were performed within 1 year 
before pregnancy. Systolic dysfunction of the left ventricle was observed in 12.2% of 
women and 14.9% had RV systolic dysfunction. Sinus rhythm was present in 94.8% of 
women. Use of cardiac medication (≤ 1 year before pregnancy) was reported in 25.9% 
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of women. Beta blockers were used by 18.5% of women, 8.3% used anticoagulants or 
platelet inhibitors, 1.9% used diuretics, 0.9% used angiotensin II antagonists and 0.9% 
used calcium channel blockers.
Tabel 1. Type of underlying congenital heart disease (CHD) in 138 pregnant women
CHD type N (%)
 Left-sided lesions 44 (31.9)
Aortic coarctation after repair 17 (12.2)
Aortic valve stenosis / Bicuspid aortic valve 26 (18.7)
Mitral valve disease 1 (0.7)
 Right-sided lesions 41 (29.7)
 Double chambered right ventricle 1 (0.7)
Ebstein's anomaly 5 (3.6)
Pulmonary atresia 3 (2.2)
Pulmonary valve stenosis 13 (9.4)
Tetralogy of Fallot after repair 19 (13.7)
 Shunt lesions 38 (27.5)
Abnormal pulmonary venous return 2 (1.4)
Aortopulmonary window 1 (0.7)
Atrial septum defect 12 (8.7)
Atrioventricular septal defect 9 (6.5)
Ventricular septal defect 14 (10.1)
 Connective tissue disorder 3 (2.2)
 Complex CHD 12 (8.7)
Transposition of great arteries (Mustard/Senning) 3 (2.2)
Transposition of great arteries (arterial switch) 3 (2.2)
Congenital aberrant coronary arteries 1 (0.7)
Congenitally corrected transposition of great arteries 3 (2.2)
Right ventricular hypoplasia with pulmonary valve ste-
nosis and bilaterall Glenn procedure 
1 (0.7)
Truncus arteriosus 1 (0.7)
RV, right ventricular; TGA, transposition of the great arteries.
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Table 2. Demographic and clinical characteristics in 138 pregnant women with congenital heart 
disease
N (%)
Maternal age (years ± SD) 29.3 ± 3.9









 I (low risk) 11 (8.0)
II (moderately high risk) 102 (73.9)
III (high risk) 23 (16.7)
IV (extremely high risk) 2 (1.4)
Medical history
 History of arrhythmia 12 (8.7)
 History of congestive heart failure 0 (0)
 History of diabetes mellitus 0 (0)
 History of hypertension 6 (4.3)
 Biological valve prosthesis 15 (10.8)
 Mechanical valve prosthesis 6 (4.3)
 ICD 1 (0.7)
 Pacemaker 3 (2.2)
Cardiac medication use prior to pregnancy* 28 (25.9)
 Beta-blocker 20 (18.5)
 Other 11 (10.2)
Echocardiographic parameters*
 Aortic valve regurgitation† 3 (3.3)
 Aortic valve stenosis‡ 8 (8.9)
 Pulmonary valve regurgitation† 15 (16.7)
 Pulmonary valve stenosis‡ 6 (6.7)
 Pulmonary atrioventricular valve regurgitation† 7 (7.8)
 Systemic atrioventricular valve regurgitation† 2 (2.2)
 Left ventricular systolic dysfunction§ 11 (12.2)
 Left ventricular hypertrophy¶ 11 (12.2)
 Right ventricular systolic dysfunction** 13 (14.9)
Data are given as mean±SD, n (%) or n/N (%). *≤1 year prepregnancy. †Moderate or severe 
regurgitation. ‡Peak gradient ≥ 36mmHg. §Ejection fraction <45%. ¶Left ventricular mass/
body surface area >95 g/m2. **Tricuspid annular plane systolic excursion <17 mm. BMI, 
body mass index; NYHA, New York Heart Association; WHO, World Health Organization.
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Relationship between cardiovascular parameters and UtA-PI
The PI of the UtAs was available for all 138 women with CHD. At 12 and 20 weeks 
of gestation, mean UtA-PI was 1.38 ± 0.56 and 0.90 ± 0.29, respectively. Abnormal 
values were reported in 4.3% and 3.1% of women (P=0.727) at 12 and 20 weeks, 
respectively. Presence of early diastolic notch was reported in 5.8% of UtA waveforms 
at 20 weeks. Maternal cardiovascular parameters prepregnancy, and at 12 weeks’ 
gestation, were correlated with UtA-PI measured at 12 and 20 weeks of gestation. 
Univariable regression analysis revealed that prepregnancy TAPSE (β= −0.027; 
P=0.022), e′ mean (β= −0.075; P=0.042) and pulmonary stenosis (β= 0.522; P=0.020) 
were associated significantly with UtA-PI measured at 12 weeks of gestation. Use of 
cardiac medication before or during pregnancy was not associated with UtA-PI at 12 
or 20 weeks’ gestation. Significant parameters and confounders considered important 
and entered into the multivariable model are presented in Table 3. E′ mean was not 
entered into the model due to the small number of women with available data (n=27) 
hampering the analysis. In this model, prepregnancy TAPSE remained associated 
significantly with UtA-PI at 12 weeks of gestation. Figure 1 shows the changes in UtA-
PI during pregnancy in women with TAPSE ≤ 20 mm and in those with TAPSE > 20 
mm prepregnancy, with a significant difference between these groups at 12 weeks’ 
gestation. History of open-heart surgery did not affect the association between TAPSE 
and UtA-PI. The following maternal prepregnancy variables were associated with UtA-
PI at 20 weeks on univariable analysis: heart rate, NYHA Class 2 and WHO Class 3. On 
multivariable analysis, NYHA Class 2 remained significant (β= 0.451; P<0.001).
Table 3 Multivariable regression analysis of association between prepregnancy variables and 
uterine artery pulsatility index at 12 weeks’ gestation in pregnant women with congenital heart 
disease
  Characteristic N* β (95% CI) P
Age at conception 138 0.013 (-0.017 – 0.043) 0.394
BMI† 93 0.013 (-0.021 – 0.048) 0.394
Parity 138 -0.101 (-0.258 – 0.056) 0.205
History of hypertension 138 0.139 (-0.405 – 0.684) 0.612
TAPSE† 83 -0.026 (-0.049 – -0.002) 0.036
Pulmonary stenosis (moderate/severe)† 90 0.411 (-0.044 – 0.866) 0.076
*Degrees of freedom=83. †Values available ≤1 year prepregnancy. BMI, body mass index; 
PS, pulmonary stenosis; TAPSE, tricuspid annular plane systolic excursion.
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Figure 1. Serial changes in mean uterine artery pulsatility index (UtA-PI) during pregnancy 
in women with congenital heart disease with prepregnancy tricuspid annular plane systolic 
excursion (TAPSE) ≤ 20 mm (continuous line ; n=42) and > 20 mm (interrupted line ; n=41). 
Mean UtA-PI was significantly higher in first trimester in women with prepregnancy TAPSE ≤ 20 
mm (P=0.047). Significant decrease in mean UtA-PI was observed throughout pregnancy in both 
groups (P<0.05).
Pregnancy outcome in CHD and its association with first-trimester 
UtA-PI
Pregnancy outcome data were available for all pregnancies. The number of women 
with each complication and their relationship with UtA-PI are presented in Figure 2. 
A primary cardiac complication occurred in 2.9% of women with CHD. One woman 
developed supraventricular tachycardia during pregnancy, for which cardioversion and 
an increase in metoprolol dosage were required. Two women had a thromboembolic 
event (deep venous thrombosis and arterial thrombosis in the abdominal aorta). 
NYHA class deterioration (≥2 classes) was observed in 3.6% of women. A primary 
obstetric complication occurred in 51.4% of all pregnancies. The occurrence of 
total obstetric complications, pre-eclamsia, PIH and preterm prelabor rupture of 
membranes were significantly associated with increased UtA-PI at 12 weeks’ gestation 
(Figure 2). Vacuum or forceps extraction was performed in 8.7% of pregnancies and 
Cesarean section was performed in 28.2% (15.2% planned and 13.0% emergency). 
Mean gestational age at delivery was 37 + 6 weeks (± 3 weeks). Neonatal complications 
occurred in 36% (50 of 140) of live births. Of all pregnancies, 18% resulted in preterm 
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birth, of which 10 were spontaneous and 15 were iatrogenic (six because of maternal 
indication and nine because of fetal indication). There were five (3.6%) perinatal and 
one (0.7%) infant deaths. Causes of death were: pregnancy termination because of 
complex CHD; intrauterine death because of retroplacental hematoma; immature 
delivery; and three deaths because of respiratory distress syndrome associated 
with prematurity. Mean birth weight was 2981.3 ± 820.3 g. Admission to a neonatal 
intensive care unit was needed for 20.0% of neonates. Congenital heart disease was 
suspected before birth and confirmed in 4.3%of neonates.
Figure 2. Forest plot of uterine artery pulsatility index (UtA-PI) at 12 weeks’ gestation in 
pregnant women with congenital heart disease, according to presence or absence of pregnancy 
complications. *Fetal and neonatal death. †Death or birth <22 weeks’ gestation excluded. NRDS, 




This study investigated the relationship between preexisting suboptimal maternal 
cardiac function and UtA-PI measured in the first trimester in women with CHD. 
The results suggest that RV dysfunction before pregnancy may impact placentation, 
resulting in increased resistance in the UtA flow that can be documented in the 
first trimester of pregnancy from about 12–13 weeks’ gestation. This, in turn, was 
associated with increased risk of maternal complications and, to a lesser extent, 
neonatal complications. First-trimester screening widens the window of opportunity 
for institution of preventive measures. The function of the heart is closely related to the 
function of other organs. In patients with heart failure, reduced perfusion and venous 
congestion are the most important determinants of liver and kidney dysfunction.9,10 
Similar hemodynamic interactions may occur between the heart and the placenta. In 
fact, the autoregulatory capacity of the uteroplacental circulation is limited, implying 
that placental function is directly dependent on maternal cardiac performance24,25. 
The relationship between maternal hemodynamics and placental function has been 
studied in pregnant women with heart disease, those with pre-eclampsia and in healthy 
women.1,11,12,26–29 We have demonstrated previously an association between maternal 
cardiovascular function in women with CHD and impaired uteroplacental circulation 
in the second and third trimesters.1,6,7 In the current study, we found an association 
between subclinical prepregnancy RV dysfunction and impaired uteroplacental 
circulation as early as the first trimester of pregnancy. This early documented 
association supports the hypothesis that maternal cardiac function before pregnancy 
may influence placental development and function and play a role in the occurrence 
of pregnancy-related complications affecting the mother and the fetus. In contrast to 
our previous study, we did not find an association between prepregnancy maternal 
RV dysfunction and UtA-PI at 20 weeks’ gestation. However, the association between 
prepregnancy maternal functional class and UtA-PI at 20 weeks suggests that this 
relationship persists later in pregnancy, but is more diluted. A possible explanation for 
this difference is that women in the current study had, in general, better cardiac function 
given the lower percentage of cardiac events and the lower prevalence of abnormal 
UtA-PI measurements at 20 weeks’ gestation. Our findings also suggest that UtA-PI 
measured early in pregnancy reflects more directly impaired maternal cardiac function 
and impaired placentation, while later in pregnancy this relationship is weaker and 
umbilical artery flow becomes the strongest indicator of impaired placental function. 
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Remarkably, both in the current study and in our previous one, we found that RV 
dysfunction and not LV dysfunction was associated with impaired uteroplacental flow. 
We had postulated previously that this might be explained by a higher prevalence 
of right-sided heart disease and RV dysfunction. However, in the current study, left- 
and right-sided lesions or dysfunction were prevalent equally. Therefore, our findings 
suggest that placental development might be influenced more negatively by venous 
congestion, a typical consequence of RV dysfunction, than by impaired cardiac output. 
RV dysfunction is one of the mechanisms leading to changes in venous pressure 
resulting in venous congestion.8 Venous congestion might impair trophoblast 
invasion early in pregnancy, resulting in abnormal placentation.30 In women with pre-
eclampsia, venous hemodynamic dysfunction has been suggested and demonstrated 
to play a role in the pathophysiology of pre-eclampsia.28 Interestingly, all parameters 
that appeared to be associated with impaired uteroplacental flow on univariable and/
or multivariable regression analyses (TAPSE, pulmonary valve stenosis and E′ mean) 
may contribute to backward failure of the heart, due to increased pressures in the 
right side of the heart, and lead to venous congestion. Another hypothesis is that the 
increasing demands of placental perfusion cannot be met due to decreased cardiac 
output, as suggested by Wald et al..26 RV function might affect LV function through LV-
RV interaction, which can lead to decreased cardiac output8. Further studies including 
extensive analyses of RV function, including measures other than TAPSE, are needed 
to explore the association between RV function and uteroplacental flow found in 
the current study and to support these hypotheses. Rates of obstetric (51%) and 
neonatal (36%) complications were in line with those in previous studies of women 
with CHD1,31,32, although the cardiac event rate (3%) was lower in the present study 
than in our previous one.1 This is most likely explained by improvements in care for 
women with CHD both before and during pregnancy. In our previous study (ZAHARAII), 
women with CHD had significantly higher obstetric and neonatal complication rates 
than did healthy pregnant women (58.9% vs 32.9% and 35.4% vs 18.6%, respectively).1 
Since complication rates for women with CHD in the ZAHARAII and III studies are 
comparable, we assumed that the pregnant women with CHD in the current study 
were also at higher risk of obstetric and neonatal complications. It is known that 
women with CHD have an increased risk of obstetric and neonatal complications31,32 
that are related to inadequate uteroplacental perfusion.33 We demonstrated, in this 
study, that women with CHD at high risk of obstetric complication can initially be 
identified in the first trimester, which allows for closer surveillance. Recent literature 
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on women without heart disease indicates that first-trimester screening for late 
pregnancy complications is feasible and that preventive strategies are effective in 
reducing the prevalence of severe early-onset pre-eclampsia.34 Whether the same 
applies to women with CHD deserves further investigation.
Strengths and limitations
To our knowledge, this study is the first to investigate the association between maternal 
cardiac function and UtA-PI measured in the first trimester of pregnancy inwomenwith 
CHD. One limitation is that the population of women with CHD is heterogeneous, 
although the distribution of CHD types was similar to that in the larger Dutch national 
congenital database (CONCOR). Another limitation is that complete data were not 
available in all cases, as inclusion occurred after conception, and missing data on 
prepregnancy function (including TAPSE) was therefore inevitable, which limited the 
statistical power. Moreover, we were able to analyze only TAPSE as a RV function 
parameter. More research on RV function in pregnancy is needed before we can 
draw firm conclusions on the influence of impaired RV function on the placentation 
process.
Conclusions
In women with CHD, maternal RV dysfunction before pregnancy seems to impact 
placentation, resulting in increased resistance in UtA flow. This in turn is associated 
with pregnancy complications, but not with increased neonatal risks. Although the 
clinical relevance of these findings cannot yet be foreseen, the data are important for 
understanding the mechanism underlying adverse maternal (and neonatal) outcomes 
in women with CHD, and suggest that early monitoring of UtA flow may be useful in 
women with pre-existing subclinical RV dysfunction to identify high-risk pregnancies 
and possibly institute preventive strategies.
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